Literature DB >> 597473

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.

N Thatcher, M K Palmer, N Gasiunas, D Crowther.   

Abstract

Thirty-eight patients with metastatic melanoma were investigated for lymphocyte function immediately prior to chemo-immunotherapy. The pre-treatment immune tests were compared with normal control values and with response to therapy. The "non-responder" group (but not "responder") had significantly reduced values for lymphocyte, null-cell and E-rosette-cell counts compared with controls. Lymphocytoxicity ( using a Chang target cell) showed the same pattern, with depression of direct and K-cell cytotoxic capacity in non-responders compared with controls. Eight patients were studied sequentially whilst on treatment, and demonstrated considerable change (not statistically significant) in lymphocytotoxicity, an untreated "control" patient showed little variation. "Recall"-antigen skin testing showed no statistically significant difference between the patient groups. The data indicate that "non-T-cell activity" may be associated with response to chemo-immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 597473      PMCID: PMC2025560          DOI: 10.1038/bjc.1977.258

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  PHYTOHAEMAGGLUTININ-INDUCED CYTOTOXIC ACTION OF NORMAL LYMPHOID CELLS ON CELLS IN TISSUE CULTURE.

Authors:  G HOLM; P PERLMANN; B WERNER
Journal:  Nature       Date:  1964-08-22       Impact factor: 49.962

Review 2.  Cytotoxic effects of lymphoid cells in vitro.

Authors:  P Perlmann; G Holm
Journal:  Adv Immunol       Date:  1969       Impact factor: 3.543

3.  Binding of sheep red blood cells to a large population of human lymphocytes.

Authors:  W H Lay; N F Mendes; C Bianco; V Nussenzweig
Journal:  Nature       Date:  1971-04-23       Impact factor: 49.962

4.  Cytotoxic lymphocytes from rats depleted of thymus processed cells.

Authors:  B Harding; D J Pudifin; F Gotch; I C MacLennan
Journal:  Nat New Biol       Date:  1971-07-21

Review 5.  Immunological factors which influence response to immunotherapy in malignant melanoma.

Authors:  D Morton; F R Eilber; R A Malmgren; W C Wood
Journal:  Surgery       Date:  1970-07       Impact factor: 3.982

6.  T and B lymphocytes in breast cancer stage relationship and abrogation of T-lymphocyte depression by enzyme treatment in vitro.

Authors:  R H Whitehead; J Thatcher; C Teasdale; G P Roberts; L E Hughes
Journal:  Lancet       Date:  1976-02-14       Impact factor: 79.321

7.  Immunologic studies in patients with malignant melanoma in Uganda.

Authors:  J L Ziegler; M G Lewis; J M Luyombya; J W Kiryabwire
Journal:  Br J Cancer       Date:  1969-12       Impact factor: 7.640

8.  Lymphoid cells mediating tumor-specific cytotoxicity to carcinoma of the urinary bladder. Separation of the effector population using a surface marker.

Authors:  C O'Toole; V Stejskal; P Perlmann; M Karlsson
Journal:  J Exp Med       Date:  1974-03-01       Impact factor: 14.307

9.  A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization.

Authors:  C Bianco; R Patrick; V Nussenzweig
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

10.  Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.

Authors:  M Jondal; G Holm; H Wigzell
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  8 in total

1.  Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.

Authors:  N Thatcher; R Swindell; D Crowther
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

2.  Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.

Authors:  N Thatcher; R Swindell; D Crowther
Journal:  Clin Exp Immunol       Date:  1979-01       Impact factor: 4.330

3.  Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.

Authors:  N Thatcher; R Swindell; D Crowther
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

4.  Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination.

Authors:  Annkristin Heine; Chrystel Flores; Heidrun Gevensleben; Linda Diehl; Mathias Heikenwalder; Marc Ringelhan; Klaus-Peter Janssen; Ulrich Nitsche; Natalio Garbi; Peter Brossart; Percy A Knolle; Christian Kurts; Bastian Höchst
Journal:  Oncoimmunology       Date:  2017-06-16       Impact factor: 8.110

5.  Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.

Authors:  N Thatcher; R Swindell; D Crowther
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

6.  Cell mediated immune response in miniature Sinclair swine bearing cutaneous melanomas.

Authors:  D H Jones; M S Amoss
Journal:  Can J Comp Med       Date:  1982-04

7.  Natural killer activity in patients with biopsy-proven liver disease.

Authors:  S Serdengecti; D B Jones; G Holdstock; R Wright
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

8.  Lymphocyte response to mitogens in patients with malignant melanoma.

Authors:  M Noack; H Bloedhorn; W P Herrmann
Journal:  Arch Dermatol Res       Date:  1979-05-04       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.